The ROBUST study (NCT02285062) is a randomized, double-blind, placebo-controlled phase III study assessing R-CHOP plus lenalidomide 10 mg o.d. on days 1–10/21-day cycle (R2-CHOP) versus R-CHOP in ABC subtype DLBCL assessed by GEP conducted screening [38]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.